Clinical Trial Update: A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs [Phase 3]

View source ↗

Summary

Phase 3 trial comparing upadacitinib to placebo in adults with rheumatoid arthritis who had an inadequate response or intolerance to biologic DMARDs, ongoing cs…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-10-07